BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

...round to develop a platform that targets drugs to macrophages via the macrophage surface receptor CD163...
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: CD163

...Neurology INDICATION: Parkinson's disease (PD) Rat studies suggest CD163-targeting liposomes loaded with anti-inflammatory agents could help...
...anti-inflammatory agents could help treat PD. In a rat model of PD, numbers of striatum-infiltrating CD163-positive...
...include testing CD163-targeting liposomes loaded with other anti-inflammatory agents in the models of PD. TARGET/MARKER/PATHWAY: CD163...
BioCentury | Jan 6, 2011
Strategy

LU Bio: Swedish hybrid

...a loss, but the latter company continues to develop a drug delivery platform that targets CD163...
BioCentury | Apr 24, 2006
Product Development

Secondary success

...CRx-170 failed to meet the predefined primary endpoint of a significant decrease in circulating monocyte CD163...
...single-blind design of the study, "we did not assign the same type of importance to CD163...
...was "more complex than we initially appreciated" because it turned out that "the meaning of CD163...
BioCentury | Apr 24, 2006
Clinical News

CRx-170: Phase IIa data

...patients, one week dosing of CRx-170 missed the primary endpoint of change in circulating monocyte CD163...
...Combination of low-dose budesonide and low-dose nortriptyline Indication: Treat asthma Endpoint: Change in circulating monocyte CD163...
BioCentury | Apr 19, 2006
Clinical News

CombinatoRx's CRx-170 misses endpoint

...CRXX's CRx-170 missed the primary endpoint of change in circulating monocyte CD163 in a Phase II...
Items per page:
1 - 6 of 6